Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
16-18 March, 2026
Food Ingredients Chin... Food Ingredients China
Not Confirmed
Not Confirmed
17-19 March, 2026
Rare Disease SummitRare Disease Summit
Not Confirmed
Not Confirmed
17-19 March, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
BePharma
Not Confirmed
Contact SupplierBePharma
Industry Trade Show
Not Confirmed
16-18 March, 2026
Food Ingredients Chin... Food Ingredients China
Industry Trade Show
Not Confirmed
17-19 March, 2026
Rare Disease SummitRare Disease Summit
Industry Trade Show
Not Confirmed
17-19 March, 2026
Digital content
NEWS #PharmaBuzz
17 Dec 2025
// PRESS RELEASE
https://ir.acrivon.com/news-releases/news-release-details/acrivon-therapeutics-announce-clinical-update-its-ongoing-phase
13 Nov 2025
// PRESS RELEASE
https://ir.acrivon.com/news-releases/news-release-details/acrivon-therapeutics-reports-third-quarter-2025-financial
26 Mar 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/acrivon-stops-developing-lilly-castoff-ovarian-bladder-cancer-focus-endometrial
24 Apr 2024
// PRESS RELEASE
https://ir.acrivon.com/news-releases/news-release-details/acrivon-therapeutics-reports-initial-positive-clinical-data-acr
16 Apr 2024
// PRESS RELEASE
https://ir.acrivon.com/news-releases/news-release-details/acrivon-therapeutics-host-corporate-rd-event-highlighting-ap3
10 Apr 2024
// PRESS RELEASE
https://ir.acrivon.com/news-releases/news-release-details/acrivon-therapeutics-presents-data-aacr-annual-meeting
Drugs in Development
Details:
ACR-368 (prexasertib), a potent, selective CHK1/2 inhibitor, is deprioritized for ovarian and bladder cancers as targets and will be redirected to testing in endometrial cancer.
Lead Product(s): Prexasertib,Gemcitabine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 26, 2025
Lead Product(s) : Prexasertib,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Acrivon Stops Testing Lilly Castoff for Ovarian, Bladder Cancer
Details : ACR-368 (prexasertib), a potent, selective CHK1/2 inhibitor, is deprioritized for ovarian and bladder cancers as targets and will be redirected to testing in endometrial cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 26, 2025
Details:
ACR-2316 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Lead Product(s): ACR-2316
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 31, 2024
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
Details : ACR-2316 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 31, 2024
Details:
Gemcitabine is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.
Lead Product(s): Gemcitabine,ACR-368
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cytotoxic Drug
Recipient: Moffitt Cancer Center
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 19, 2024
Lead Product(s) : Gemcitabine,ACR-368
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Moffitt Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
Details : Gemcitabine is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
September 19, 2024
Details:
The proceeds will advance ACR-368 (prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in Phase 2 trials, and its preclinical pipeline, including ACR-2316.
Lead Product(s): Prexasertib,Gemcitabine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: RA Capital Management
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 09, 2024
Lead Product(s) : Prexasertib,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : RA Capital Management
Deal Size : $130.0 million
Deal Type : Private Placement
Acrivon Therapeutics Announces $130 Million Private Placement Financing
Details : The proceeds will advance ACR-368 (prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in Phase 2 trials, and its preclinical pipeline, including ACR-2316.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 09, 2024
Details:
Acrivon is currently advancing its lead candidate, ACR-368 (prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types.
Lead Product(s): Prexasertib,Gemcitabine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Jefferies
Deal Size: $99.4 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 15, 2022
Lead Product(s) : Prexasertib,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Jefferies
Deal Size : $99.4 million
Deal Type : Public Offering
Acrivon Therapeutics Announces Pricing of Initial Public Offering
Details : Acrivon is currently advancing its lead candidate, ACR-368 (prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 15, 2022
Details:
ACR-368 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.
Lead Product(s): ACR-368
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cytotoxic Drug
Sponsor: GOG Foundation
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 21, 2022
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Details : ACR-368 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
September 21, 2022
Details:
Proceeds will support the clinical development of advanced Phase 2 lead asset ACR-368, a potent DNA Damage Response (DDR) inhibitor clinically validated in solid cancers, and in-house drug pipeline driven by the company’s proprietary platform technology.
Lead Product(s): Prexasertib,Gemcitabine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Wellington Management Company
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 11, 2021
Lead Product(s) : Prexasertib,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Wellington Management Company
Deal Size : $100.0 million
Deal Type : Series B Financing
Details : Proceeds will support the clinical development of advanced Phase 2 lead asset ACR-368, a potent DNA Damage Response (DDR) inhibitor clinically validated in solid cancers, and in-house drug pipeline driven by the company’s proprietary platform technolog...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 11, 2021
Details:
Acrivon intends to develop prexasertib (also called ACR-368) in accelerated clinical trials treating patients whose tumors are driven by, and depend on, dysregulated CHK1 and CHK2 using the OncoSignature® test.
Lead Product(s): Prexasertib,Gemcitabine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 29, 2021
Lead Product(s) : Prexasertib,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Acrivon intends to develop prexasertib (also called ACR-368) in accelerated clinical trials treating patients whose tumors are driven by, and depend on, dysregulated CHK1 and CHK2 using the OncoSignature® test.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 29, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
